Alivus Life Sciences Q1 FY27 net profit up 32% YoY to Rs 160 crore

Pat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

ALIVUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.3%Reaction day

₹1115.00

prior close

₹1135.50

announcement price

After-mkt

timing

Nifty Microcap 250market+1.1%+2.2% vs market

Pharmaceuticals peers, median of 164sector+0.1%+3.2% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 3.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-1.1

15m

-1.3

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.3+1.1+2.2+0.1+3.2

Next day

+9.2+2.4+6.8+1.1+8.1

+20.2+2.9+17.3+1.0+19.2

+19.5+4.2+15.3+1.1+18.4

+18.5+4.6+13.9+1.2+17.4

+18.6+4.6+14.0+1.4+17.2

+24.3+4.4+19.9+2.2+22.1

15d

+21.7+5.7+16.0+1.3+20.4

+25.6+6.6+19.0+2.0+23.5

+23.7+5.4+18.3+3.0+20.7

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Revenue from operations grew 6.4 percent YoY to Rs 640.4 crore from Rs 601.8 crore. Net profit rose 31.7 percent YoY to Rs 160.1 crore vs Rs 121.5 crore. EPS at Rs 13.04 vs Rs 9.91. Sequential revenue dipped 7 percent from Q4 FY26. No exceptional items this quarter. Auditor Walker Chandiok gave an unmodified review.

Likely market impact

Strong profit growth driven by margin expansion despite modest revenue growth. Sequential dip is normal quarter on quarter variation.